Fig. 3

Serum and peritoneal fluid concentrations of IGF-1 and its gene and protein expression by PFMCs, PBMCs and ESCs. Serum concentrations of IGF-1 were measured in 70 endometriotic and 70 non-endometriotic participants. Peritoneal fluid concentrations of IGF-1 were measured in 36 endometriotic and 30 non-endometriotic participants. The basal gene and protein expression of IGF-1 were measured in PFMCs (n = 10), PBMCs (n = 10), EESCs (n = 8), and EuESCs (n = 10) from patients with endometriosis and PFMCs (n = 7), PBMCs (n = 10), and CESCs (n = 10) from non-endometriotic women. (Aa) serum concentration of IGF-1, (Ab) peritoneal concentration of IGF-1, (Ac) serum concentration of IGF-1 in different stages of endometriosis, (Ad) serum concentration of IGF-1 in different menstrual cycles, (Ba) IGF-1 gene expression by PFMCs, (Bb) IGF-1 protein expression by PFMCs, (Bc) IGF-1 gene expression by PBMCs, (Bd) IGF-1 protein expression by PBMCs, (Be) IGF-1 gene expression by ESCs, (Bf) IGF-1 protein expression by ESCs. *P < 0.05, **P < 0.01. A and B parts analyzed by parametric and non-parametric tests, respectively. ^†P–C: Proliferative phase of the control group, S-C: Secretory phase of the control group, P–E: Proliferative phase of endometriosis patients, S–E: Secretory phase of endometriosis patients